https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / BioDrugs 2005;19(5):289-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / BioDrugs 2005;19(5):289-972005-01-01 00:00:002019-02-15 09:25:42Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Anticancer Res. 2005 Jan-Feb;25(1B):443-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Anticancer Res. 2005 Jan-Feb;25(1B):443-92005-01-01 00:00:002005-01-01 00:00:00Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Immunol. Invest. 2005;34(3):245-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Immunol. Invest. 2005;34(3):245-582005-01-01 00:00:002005-01-01 00:00:00Comparison of the anti-tumor effects of various whole-body hyperthermia protocols: correlation with HSP 70 expression and composition of splenic lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Strahlenther Onkol 2005 Jan;181(1):35-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Strahlenther Onkol 2005 Jan;181(1):35-412005-01-01 00:00:002019-02-15 10:00:38Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-17 / Cancer Immunol. Immunother. 2005 Jul;54(7):663-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-17 / Cancer Immunol. Immunother. 2005 Jul;54(7):663-702004-12-17 00:00:002019-02-15 09:17:04Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-52004-12-01 00:00:002019-02-15 08:35:32Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-82004-12-01 00:00:002019-02-15 09:24:22Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Hepatol. 2004 Dec;41(6):999-1007
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Hepatol. 2004 Dec;41(6):999-10072004-12-01 00:00:002019-02-15 09:11:52Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-272004-12-01 00:00:002004-12-01 00:00:00Current approaches in ovarian cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-28 / Nat. Med. 2004 Dec;10(12):1359-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-28 / Nat. Med. 2004 Dec;10(12):1359-652004-11-28 00:00:002019-02-15 09:15:21Therapeutic dendritic-cell vaccine for chronic HIV-1 infection
